Anika Therapeutics Inc
ANIKAnika Therapeutics Inc (ANIK) is a biotechnology company specializing in the development and commercialization of innovative products for tissue protection, healing, and repair. It focuses on orthopedics and ophthalmology, offering advanced bioengineered solutions based on hyaluronic acid and other biomaterials to improve patient outcomes.
Company News
Anika Therapeutics granted 3,360 restricted stock units to a newly hired non-executive employee on June 1, 2026, as part of their employment compensation package. The RSUs will vest in three equal installments over three years, subject to continuous service.
Law firm Bragar Eagel & Squire is investigating Anika Therapeutics for potential securities law violations following the failure of its Hyalofast clinical trial to meet pre-specified endpoints. The announcement on July 30, 2025, caused Anika's stock to plummet 27.42% to $8.10 per share. The firm is seeking investors who suffered losses to partici...
Law firm investigating potential securities fraud at Anika Therapeutics after clinical trial results showed missed endpoints, causing stock price to drop 27.42% on July 30, 2025.
Anika Therapeutics announced clinical trial results for Hyalofast that did not meet pre-specified endpoints, causing a 27.42% stock price drop and triggering a potential legal investigation.
Anika Therapeutics granted 2,500 non-statutory stock options to a newly hired non-executive employee at $9.15 per share, with a vesting schedule over three years and a ten-year expiration.
